Abstract
Metabolic Syndrome (MetS) is a complex disorder defined by the aggregation of interconnected cardiometabolic risk factors which increase the risk of diabetes mellitus type 2 and cardiovascular disease (CVD). MetS is currently a matter of concern and it will continue to be in the future, since there is likely to be a dramatic increase in its prevalence, and subjects with MetS will have an increased risk of mortality, mainly through CVD. Moreover, the implications on the global health burden and the worldwide epidemic of this complex disorder will impact greatly on socioeconomic cost. MetS is therefore a matter of serious concern and we need to understand its etiology in order to improve strategies of treatment and prevention. In this regard, postprandial lipemia has increased in importance over the last few years as it has been demonstrated to influence the development of atherosclerosis. In addition, in modern times, fasting is not the typical physiological state of humans; in fact, they spend most of the time in the postprandial state. However, although it is obvious that postprandial lipemia is present in conditions of obesity, little is known about the relevance of postprandial lipemia in MetS. In the current review, we will explore some aspects of postprandial lipemia which could be of interest for understanding the pathogenesis of this complex disorder and which may help us advance towards more personalized nutrition.
Keywords: Endothelial dysfunction, inflammation, metabolic syndrome, nutrigenetics, oxidative stress, postprandial lipemia.
Current Vascular Pharmacology
Title:Relevance of Postprandial Lipemia in Metabolic Syndrome
Volume: 11 Issue: 6
Author(s): Antonio Garcia-Rios, Javier Delgado-Lista, Pablo Perez-Martinez, Nieves Delgado-Casado, Francisco Perez-Jimenez and Jose Lopez-Miranda
Affiliation:
Keywords: Endothelial dysfunction, inflammation, metabolic syndrome, nutrigenetics, oxidative stress, postprandial lipemia.
Abstract: Metabolic Syndrome (MetS) is a complex disorder defined by the aggregation of interconnected cardiometabolic risk factors which increase the risk of diabetes mellitus type 2 and cardiovascular disease (CVD). MetS is currently a matter of concern and it will continue to be in the future, since there is likely to be a dramatic increase in its prevalence, and subjects with MetS will have an increased risk of mortality, mainly through CVD. Moreover, the implications on the global health burden and the worldwide epidemic of this complex disorder will impact greatly on socioeconomic cost. MetS is therefore a matter of serious concern and we need to understand its etiology in order to improve strategies of treatment and prevention. In this regard, postprandial lipemia has increased in importance over the last few years as it has been demonstrated to influence the development of atherosclerosis. In addition, in modern times, fasting is not the typical physiological state of humans; in fact, they spend most of the time in the postprandial state. However, although it is obvious that postprandial lipemia is present in conditions of obesity, little is known about the relevance of postprandial lipemia in MetS. In the current review, we will explore some aspects of postprandial lipemia which could be of interest for understanding the pathogenesis of this complex disorder and which may help us advance towards more personalized nutrition.
Export Options
About this article
Cite this article as:
Garcia-Rios Antonio, Delgado-Lista Javier, Perez-Martinez Pablo, Delgado-Casado Nieves, Perez-Jimenez Francisco and Lopez-Miranda Jose, Relevance of Postprandial Lipemia in Metabolic Syndrome, Current Vascular Pharmacology 2013; 11 (6) . https://dx.doi.org/10.2174/15701611113116660172
DOI https://dx.doi.org/10.2174/15701611113116660172 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Annual Trends in Use of Periconceptional Folic Acid and Birth Prevalence of Major Congenital Malformations
Current Drug Safety Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes
Current Pharmaceutical Design The Sodium-Iodide Symporter
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Effectiveness of Nurse- and Pharmacist-Directed Care in Diabetes Disease Management:A Narrative Review
Current Diabetes Reviews Serum Zinc and β D Glucuronidase Enzyme Level in Type 2 Diabetes Mellitus with Periodontitis
Current Diabetes Reviews EEG Upper/Low Alpha Frequency Power Ratio and the Impulsive Disorders Network in Subjects with Mild Cognitive Impairment.
Current Alzheimer Research Approaches to the Pharmacological Modulation of Plasmacytoid Dendritic Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Early Vascular Ageing (EVA): Definitions and Clinical Applicability
Current Hypertension Reviews What Metabolic Syndrome Contributes to Brain Outcomes in African American & Caucasian Cohorts
Current Alzheimer Research Identifying Novel Targets for Treatment of Liver Fibrosis: What Can We Learn from Injured Tissues which Heal Without a Scar?
Current Drug Targets The Evidence Base for Revascularisation of Chronic Total Occlusions
Current Cardiology Reviews A Critical and Comprehensive Insight on Heme Oxygenase and Related Products Including Carbon Monoxide, Bilirubin, Biliverdin and Ferritin in Type-1 and Type-2 Diabetes
Current Pharmaceutical Design Glucose Lowering Activity of Aqueous Ammodaucus leucotrichus Extract in Diabetic Rats
Cardiovascular & Hematological Disorders-Drug Targets Sensors Based On Carbon Nanotubes and Their Applications: A Review
Current Nanoscience The Renin-Angiotensin System and Advanced Glycation End-Products in Diabetic Retinopathy: Impacts and Synergies.
Current Clinical Pharmacology Dissolution Rate Enhancement of Repaglinide Using Dietary Fiber as a Promising Carrier
Current Drug Delivery Role of Hyperglycaemia in Pathogenesis of Diabetic Cardiovascular Disease
Vascular Disease Prevention (Discontinued) Structure-Function Relationships and Clinical Applications of L-Asparaginases
Current Medicinal Chemistry Repositioning the Old Fungicide Ciclopirox for New Medical Uses
Current Pharmaceutical Design Herbal Drugs for Diabetic Treatment: An Updated Review of Patents
Recent Patents on Anti-Infective Drug Discovery